Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharm #2 > L13 concepts > Flashcards

L13 concepts Flashcards

1
Q

5 steps in Neurotransmission

A
  1. NT synthesis
  2. Vesicular Storage
  3. Synaptic Release
  4. Binding to receptor
  5. Termination of transmission
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Requirements for NT synethesis

A

precursors
transport into the cell
enzymatic action

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Thing that can affect NT synethesis

A
  1. therapeutic drugs can inhibit enzymes involved
  2. dietary intake of certain amino acids can influence availability (low tryptophan intake can reduce serotonin)
  3. Precursor loading- can increase neurotransmission (L-DOPA in parkinson’s disease)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

which NT’s are stored in vesicles?

A

All except gases and some nucleosides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the benefits to storing NTs in vesicles

A

protects them from degradation by cytosolic enzymes and concentrates them for release (if storage transporters are inhibited then NTs get degraded)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Synaptic Release

A

Depolarization of the nerve terminal > Ca channels open and Ca influx > SNARE proteins on the vessel interact with SNARE proteins on the membrane > rapid release of NTs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Boxulinum toxin

A

degrades SNAREs of the cholinergic neuromuscular junction resulting in skeletal muscle paralysis. Can be used to treat muscle spasms

Endocytosed into cholinergic neurons
Degrades SNARES
Prevents calcium-dependent exocytosis of neurotransmitter

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

amphetamine synaptic release

A

has affinity for monoamine re-uptake transporters

leads to transporter phosphorylation -which reverses the direct of NT transport

probably also inhibits vesicular uptake proteins

calcium-independent release of neurotransmitter (no voltage change or Ca influx)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

SNARES

A

Enable calcium-dependent docking of vesicle with pre-synaptic membrane

Enable exocytosis of neurotransmitter

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

indirect acting drugs

A

can increase neurotransmission and increase the effects of activating a receptor by stimulating the release of endogenous NT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

receptor binding

A

can bind receptors on pre and post synaptic cell membranes

drugs that bind directly to receptors provide the most selective manipulation of synaptic transmission

drugs acting on pre-synaptic receptors to modulate NT release can contribute to some side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

3 mechanisms for Termination of NT action

A
  1. reuptake (can occur at the pre-synaptic nerve terminal, the post-synaptic cell or the surrounding glial cells depending on the location of the reuptake protein)
  2. Diffusion (out of the synaptic cleft)
  3. Metabolic transformation and degradation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Dopamine is made from what precursor and by what enzyme?

A

Tyrosine via tyrosine hydroxylase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Dopamine is a precursor to what molecules

A

norepinephrine and epinephrine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

how is epinephrine formed

A

tyrosine > DOPA > dopamine > norepinephrine > epinephrine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

rate limiting step in catecholamine production

A

Hydroxylation of tyrosine by tyrosine hydroxylase

17
Q

Metyrosine

A

binds tyrosine hydroxylase but cannot be transformed to DOPA, decreasing dopamine production. Used for hypertension bc it decreases the NE produced

18
Q

L-DOPA

A

a precursor to dopamine. Used to treat Parkinson’s disease but increasing the amount of dopamine.

DOPA loading can have adverse effects of the CV system due to increased NE in the peripheral autonomic nerves

19
Q

carbidopa

A

blocks the conversion of L-DOPA to dopamine.

does not cross the BBB. Can be used to decrease the cardiovascular side effects of L-DOPA in peripheral adrenergic nerves

20
Q

B-hydroxylase what does it do and where is it located?

A

It transforms dopamine to norepinephrine. It is located within the vesicle so that the NE is not degraded by cytosolic enzymes

21
Q

Vesicular monoamine transporter (VMAT)

A

is responsible for transporting dopamine into synaptic vesicles. Is specific to monamines (serotonin, NE, histamine, and dopamine)

22
Q

reserpine

A

blocks VMAT resulting in depletion of monoamines (NE, DA, and serotonin).

can cross the BBB and block monoamine vesicular uptake in the CNA neurons contributing to depression

used at low doses to treat hypertension

23
Q

Bretylium

A

inhibits excitability of the nerve terminal membrane and reduces neurotransmitter release.

affects adrenergic neurotransmission ( taken up by transporters that normally take up NE)

reduces ventricular arrhythmias

24
Q

primary mode of terminating monoamine actions

A

reuptake

25
Q

catecholamine-O-methyltransferase (COMT)

A

an enzyme in the plasma that inactivates NE by metabolism. The main termination of exogenously administered NE.

metabolizes circulating monomaines (exogenous and released by the adrenal gland)

26
Q

Monamine Oxidase (MAO)

A

oxidizes norepinephrine and dopamine within the cytoplasm that is not transported into vesicles fast enough

27
Q

cocaine

A

inhibits re-uptake of monoamines including NE, dopamine and serotonin

28
Q

Common mechanism of drugs used to treat depression and anxiety

A

blocking/inhibiting monoamine reuptake

must be able to cross the BBB

can have significant systemic side effects (particularly CV which is richly innervated by noradrenergic neurons)

29
Q

phenylephrine

A

drug that was developed to be resistant to COMT degradation and therefore has a longer half-life

activates adrenergic receptors

30
Q

MAO inhibitors

A

lead to increased catecholamines in the cytoplasm.
As NE accumulates in the cytoplasm the transporter protein reverses direction leading to expulsion of NE into the synapse.

31
Q

Tyramine

A

comes form a dietary source. normally has first pass metabolism by MAOs in the liver.

when MAOs are inhibited- tyramine accumulates and is transported into adrenergic cells where it competes with NE for transport into synaptic vesicles resulting in even higher level of cytoplasmic NE than with MAO inhibitors alone. Reversal of the reuptake transporter can then lead to a hypertensive crisis

32
Q

neuropeptides

A

required longer increases in Ca to stimulate peptide release (bc they must travel further) and often produced within other neuronal types and are co-released when the nerve terminal is activated. therefore drugs that target membrane ion channels also affect neuropeptides (bertylium)

33
Q

challenge for making peptigergic analogs

A

the are large and we don’t fully understand how they interact with their receptors and the cannot cross the BBB

therefore many non-peptidergic receptor agonist and antagonist have been developed for penetration into the CNS

34
Q

naloxone

A

small lipophilic molecule used to reverse opioid overdose.

35
Q

naltrexone

A

longer duration of action than naloxone and is used in the treatment of opiate addiction and alcoholism

36
Q

ways neuropeptides differ from classical

neurotransmission

A

Requires mRNA for synthesis
Peptidases required to make final neurotransmitter*
Stored in “large dense core vesicles”
Made in soma and transported
Stored away from synapse, and requires longer stimulus for release
Travel farther to bind receptor*
Non-specific peptidase-induced metabolism

Pharm #2 (13 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions